摘要
目的研究硫酸依替米星致药物性肾损害的危险因素，为临床合理应用硫酸依替米星提供参考依据，减少肾损害的发生。方法查询我院2014年1月～2015年12月期间住院使用硫酸依替米星患者病历，共计789例。筛除不合格病例，最终人选63例。根据阿姆斯特丹AKI诊断标准，按治疗前、后Scr结果将出现急性肾损伤患者分为1组（n=6）和未发生急性肾损患者为2组（n=57）。采用SPSS16．0软件进行统计分析。结果6例应用硫酸依替米星治疗后发生AKI的患者，各项指标变化差异均无统计学意义（P〉0．05）。单因素分析显示高血压可能与应用依替米星治疗后致急性肾损伤相关（P〈0．05）。结论硫酸依替米星为较为安全的氨基糖苷类抗菌药物，患有高血压的感染患者应用该药物时需加强肾功能监测。
Objective To explore the risk factors for medical renal impairment induced by etimicin sulfate, so as to pro- vide references for clinical rational application of etimiein sulfate and reduce renal impairment. Methods A total of 789 cases of medical records with the use of etimicin sulfate during hospitalization from January 2014 to December 2015 in our hospital were consulted. Unqualified medical records were screened out, and 63 cases were finally selected. According to Amsterdam AKi diagnostic criteria, the patients with acute renal impairment were assigned to group 1 （n=6） and the patients with non-released acute renal impairment were assigned to group 2（n=57） via the Ser results before and after the treatment. SPSS16.0 software was applied for statistical analysis. The experiment results were represented by aver- age number_＋standard deviation, and P〈0.05 represented the differences were statistically significant. Results In the 6 patients with AKI induced by the etimicin sulfate therapy, the changes of each index were not statistically significant （P〉0.05）. According to the univariate analysis, hypertension might be associated with acute renal impairment induced by etimicin therapy （P〈0.05）. Conclusion Etimiein sulfate is a relatively safe aminoglycosides antibiotics. Renal function monitoring should be strengthened while the patients with hypertension and infection are using this drug.
出处
《中国现代医生》
2016年第20期78-80,84,共4页
China Modern Doctor
基金
山东省药学会临床药学奥赛康中青年科研资助项目(Sdpa-ask-2014-01)
关键词
依替米星
肾功能
药物性肾损害
急性肾损伤
Etimicin
Renal function
Medical renal impairment
Acute renal impairment
